Van beleggers
voor beleggers
desktop iconMarkt Monitor

Inloggen

  • Geen account? Registreren

Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 0,753 5 jul 2022 13:26
  • -0,016 (-2,08%) Dagrange 0,752 - 0,775
  • 1.086.303 Gem. (3M) 2,5M

Pharming April 2022

3.448 Posts
Pagina: «« 1 ... 144 145 146 147 148 ... 173 »» | Laatste | Omlaag ↓
  1. forum rang 6 Dr. Phil 24 april 2022 15:28
    quote:

    charlie b schreef op 24 april 2022 12:43:

    [...]
    Yep ik heb ook geen vertrouwen meer in deze CEO..trouwens ook al een tijdje...dus...hij mag voor mij morgen al dct opstappen...

    Nog steeds ? Dat heb je al 1,5 jaar.
    Blijkbaar is er wel veel vertrouwen door de grotere partijen gezien Dhr. Sijmen afgelopen jaar opnieuw tot CEO is verkozen. Misschien moet je wat aandelen bijkopen zodat je ook meer stemrecht krijgt :-)
  2. forum rang 6 Dr. Phil 24 april 2022 15:32
    quote:

    Eric de Rus schreef op 23 april 2022 22:31:

    Pharming casht in op z'n positie op Bioconnection. Geeft aan dat Pharming geld nodig heeft. Immers, als je het geld niet nodig hebt en een belang van meer dan 40% bezit eis je dat je belang niet verwatert.
    Of Pharming kan met dat bedrag een veel hoger rendement hehalen door te herinvesteren in onderzoek en ontwikkeling, dan het bedrag bij Bioconnection te laten staan. Sorry hier heb je natuurlijk wel beleggerstalent voor nodig Eric.
  3. [verwijderd] 24 april 2022 17:22
    quote:

    G. Hendriks schreef op 24 april 2022 10:53:

    [...]

    Zou het juridisch even precies moeten uitpluizen, maar ook informatie dat er een reorganisatie aankomt is m.i. voorkennis. Zo’n bericht zal immers de koers beïnvloeden. Fijn dat u de wetenschap van uw bekende meldt op dit forum. Hopelijk leest zijn baas niet mee.
    Dit nieuws is "7 apr 11:31 Novartis | Zwitserse farmaceut gaat reorganiseren" al gebracht.
  4. forum rang 6 Dr. Phil 24 april 2022 21:59
    quote:

    Eric de Rus schreef op 24 april 2022 21:28:

    O,o,o, jubelverhalen over de verkoop van Bioconnection. Ik gun jullie de pret hoor.

    Maar 1 ding, als een durfkapitalist als GIMV brood ziet in mijn investering en ik heb plm. 44% ga ik eisen stellen. Sowieso dat mijn belang niet verwatert.
    Pharming maakt zich niet zo druk als jij om zo'n habbekrats.
  5. forum rang 8 Eric de Rus 24 april 2022 22:31
    TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met its Objectives in Children Ages 2 to <12 Years of Age with Hereditary Angioedema (HAE)

    April 12, 2022
    SHP643-301 is A Multicenter, Open-Label Phase 3 Study to Evaluate Safety, PK, Pharmacodynamics, And Clinical Activity/Outcomes of TAKHZYRO for Prevention Against Acute Attacks of HAE in Pediatric Patients 2 To <12 Years of Age
    Safety Profile Was Consistent With That Seen in the Clinical Program for Patients 12 Years and Older; There Were No Serious Adverse Events
    Global Regulatory Filing for Children Ages 2 to <12 Years of Age Planned to Begin this Fiscal Year
    OSAKA, Japan and CAMBRIDGE, Massachusetts, April 12, 2022 – Takeda (TSE:4502/NYSE:TAK) today announced that the Phase 3 SHP643-301 study (NCT04070326) evaluating the safety profile and pharmacokinetics (PK) of TAKHZYRO® (lanadelumab) in patients 2 to <12 years of age is complete and has met its objectives. The safety profile was consistent with that seen in the clinical program for patients 12 years of age and older; there were no serious adverse events and no dropouts due to adverse events.1

    The study also successfully reached the secondary objective evaluating the clinical activity/outcome of TAKHZYRO in preventing hereditary angioedema (HAE) attacks as well as characterizing the pharmacodynamics of TAKHZYRO in pediatric subjects 2 to <12 years of age.

    “We are encouraged by these results, as each objective met instills further confidence in the potential to bring a treatment option to this vulnerable population,” said Ashley Yegin, Global Medical Unit Head, HAE, Global Medical Affairs, Takeda. “With more than a decade of experience and innovation in HAE, Takeda is committed to continued support for patients of all ages with this devastating condition.”

    “I’m pleased that TAKHZYRO has met these key objectives and I look forward to Takeda sharing further insights with the HAE community in the near future,” said Dr. Marcus Maurer, Professor of Dermatology and Allergy Charité – Universitätsmedizin Berlin, Germany and principal investigator of SHP643-301.

    SHP643-301, also known as the SPRING study, is a multicenter, open-label Phase 3 study to evaluate the safety, PK and PD of TAKHZYRO for prevention against acute attacks of HAE in pediatric patients 2 to <12 years of age. Participants aged 2 to < 6 years received lanadelumab at a dose of 150 milligrams (mg) every 4 weeks (q4wks) over 52-week treatment period. Participants aged 6 to <12 years received lanadelumab at a dose of 150 mg every 2 weeks (q2wks) over 52-week treatment period. This study is complete, and full results will be presented at upcoming medical meeting(s).1

    We look forward to discussing these data with global health authorities.

    Van 12 april hoor, om de slimmeriken voor te zijn.

    Maar dit is het nieuws van de concurrentie. Pharming verkoopt het "tafelzilver".
  6. forum rang 4 Jojet 25 april 2022 06:23
    quote:

    Eric de Rus schreef op 24 april 2022 22:31:

    TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met its Objectives in Children Ages 2 to <12 Years of Age with Hereditary Angioedema (HAE)

    April 12, 2022
    SHP643-301 is A Multicenter, Open-Label Phase 3 Study to Evaluate Safety, PK, Pharmacodynamics, And Clinical Activity/Outcomes of TAKHZYRO for Prevention Against Acute Attacks of HAE in Pediatric Patients 2 To <12 Years of Age
    Safety Profile Was Consistent With That Seen in the Clinical Program for Patients 12 Years and Older; There Were No Serious Adverse Events
    Global Regulatory Filing for Children Ages 2 to <12 Years of Age Planned to Begin this Fiscal Year
    OSAKA, Japan and CAMBRIDGE, Massachusetts, April 12, 2022 – Takeda (TSE:4502/NYSE:TAK) today announced that the Phase 3 SHP643-301 study (NCT04070326) evaluating the safety profile and pharmacokinetics (PK) of TAKHZYRO® (lanadelumab) in patients 2 to <12 years of age is complete and has met its objectives. The safety profile was consistent with that seen in the clinical program for patients 12 years of age and older; there were no serious adverse events and no dropouts due to adverse events.1

    The study also successfully reached the secondary objective evaluating the clinical activity/outcome of TAKHZYRO in preventing hereditary angioedema (HAE) attacks as well as characterizing the pharmacodynamics of TAKHZYRO in pediatric subjects 2 to <12 years of age.

    “We are encouraged by these results, as each objective met instills further confidence in the potential to bring a treatment option to this vulnerable population,” said Ashley Yegin, Global Medical Unit Head, HAE, Global Medical Affairs, Takeda. “With more than a decade of experience and innovation in HAE, Takeda is committed to continued support for patients of all ages with this devastating condition.”

    “I’m pleased that TAKHZYRO has met these key objectives and I look forward to Takeda sharing further insights with the HAE community in the near future,” said Dr. Marcus Maurer, Professor of Dermatology and Allergy Charité – Universitätsmedizin Berlin, Germany and principal investigator of SHP643-301.

    SHP643-301, also known as the SPRING study, is a multicenter, open-label Phase 3 study to evaluate the safety, PK and PD of TAKHZYRO for prevention against acute attacks of HAE in pediatric patients 2 to <12 years of age. Participants aged 2 to < 6 years received lanadelumab at a dose of 150 milligrams (mg) every 4 weeks (q4wks) over 52-week treatment period. Participants aged 6 to <12 years received lanadelumab at a dose of 150 mg every 2 weeks (q2wks) over 52-week treatment period. This study is complete, and full results will be presented at upcoming medical meeting(s).1

    We look forward to discussing these data with global health authorities.

    Van 12 april hoor, om de slimmeriken voor te zijn.

    Maar dit is het nieuws van de concurrentie. Pharming verkoopt het "tafelzilver".
    Je laatste zin is suggestief. Pharming heeft deze onderzoeken ook gedaan met Ruconest en bij de EMU zelfs al goedkeuring gekregen. Een paar weken geleden had Pharming een bericht over een succesvol fase 3 onderzoek (Leniolisib). Al weer vergeten...
3.448 Posts
Pagina: «« 1 ... 144 145 146 147 148 ... 173 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Pharming Group Meer »

Koers 0,753   Verschil -0,02 (-2,08%)
Laag 0,752   Volume 1.086.303
Hoog 0,775   Gem. Volume 2.458.231
5 jul 2022 13:26
Premium

Spanning stijgt rond Pharming

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium

Gerelateerde Video's

  1. video thumbnail

    Outlook Pharming

    7 juni 2018 16:58 - Vimeo

  2. video thumbnail

    Pharming: Groeiperspectieven

    13 maart 2018 22:16 - Vimeo

  3. video thumbnail

    Pharming kan verder omhoog

    27 oktober 2017 17:23 - Vimeo

  4. video thumbnail

    Arend Jan Kamp over Pharming

    26 oktober 2017 13:24 - Vimeo

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links